By Priyanjana Pramanik, MSc. A deep dive into public Facebook posts uncovers the real-world side effect patterns of GLP-1 ...

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

GLP-1 agonists are medications that primarily treat type 2 diabetes and obesity. However, recent studies suggest they can lower blood pressure, reduce inflammation and improve lipid disorders.

GLP-1 receptor agonist medications have revolutionized weight management and diabetes treatment, offering significant benefits for millions of patients worldwide. However, these powerful ...

For adults with type 2 diabetes and obesity, GLP-1 RAs are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other antidiabetic drugs.

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for ...

Glucagon-like peptide-1 (GLP-1) receptor agonists used in patients with diabetes are associated with reduced risks of dozens of outcomes—as well as increased risks of others—when compared with other ...

For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is ...

A major new study reveals that older adults with cancer and type 2 diabetes who take GLP-1 receptor agonist medications (GLP-1RAs) experience significantly better overall survival rates compared to ...

GLP-1 receptor agonists linked to lower medication use and reduced headaches, visual disturbances or blindness, and papilledema.